Enhancing the Anticancer Efficacy of Immunotherapy through Combination with Histone Modification Inhibitors

In the nucleus of each cell, the DNA is wrapped around histone octamers, forming the so-called “nucleosomal core particles„. The histones undergo various modifications that influence chromatin structure and function, including methylation, acetylation, ubiquitination, phosphoryla...

Full description

Bibliographic Details
Main Authors:	Wanyu Sun, Shuting Lv, Hong Li, Wei Cui, Lihui Wang
Format:	Article
Language:	English
Published:	MDPI AG 2018-12-01
Series:	Genes
Subjects:	histone methylation acetylation immunotherapy cancer
Online Access:	https://www.mdpi.com/2073-4425/9/12/633

id	doaj-d9622e2b728e4019b2d12b7726b5120a
record_format	Article
spelling	doaj-d9622e2b728e4019b2d12b7726b5120a2020-11-24T23:24:15ZengMDPI AGGenes2073-44252018-12-0191263310.3390/genes9120633genes9120633Enhancing the Anticancer Efficacy of Immunotherapy through Combination with Histone Modification InhibitorsWanyu Sun0Shuting Lv1Hong Li2Wei Cui3Lihui Wang4Department of Pharmacology, Shenyang Pharmaceutical University, Shenyang 110016, ChinaDepartment of Pharmacology, Shenyang Pharmaceutical University, Shenyang 110016, ChinaDepartment of Pharmacology, Shenyang Pharmaceutical University, Shenyang 110016, ChinaDepartment of Pharmacology, Shenyang Pharmaceutical University, Shenyang 110016, ChinaDepartment of Pharmacology, Shenyang Pharmaceutical University, Shenyang 110016, ChinaIn the nucleus of each cell, the DNA is wrapped around histone octamers, forming the so-called “nucleosomal core particles„. The histones undergo various modifications that influence chromatin structure and function, including methylation, acetylation, ubiquitination, phosphorylation, and SUMOylation. These modifications, known as epigenetic modifications (defined as heritable molecular determinants of phenotype that are independent of the DNA sequence), result in alterations of gene expression and changes in cell behavior. Recent work has shown that epigenetic drugs targeting histone deacetylation or methylation modulate the immune response and overcome acquired resistance to immunotherapy. A number of combination therapies involving immunotherapy and epigenetic drugs, which target histone deacetylation or methylation, are currently under various clinical/pre-clinical investigations and have shown promising anticancer efficacy. These combination therapies may provide a new strategy for achieving sustained anticancer efficacy and overcoming resistance.https://www.mdpi.com/2073-4425/9/12/633histone methylationacetylationimmunotherapycancer
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Wanyu Sun Shuting Lv Hong Li Wei Cui Lihui Wang
spellingShingle	Wanyu Sun Shuting Lv Hong Li Wei Cui Lihui Wang Enhancing the Anticancer Efficacy of Immunotherapy through Combination with Histone Modification Inhibitors Genes histone methylation acetylation immunotherapy cancer
author_facet	Wanyu Sun Shuting Lv Hong Li Wei Cui Lihui Wang
author_sort	Wanyu Sun
title	Enhancing the Anticancer Efficacy of Immunotherapy through Combination with Histone Modification Inhibitors
title_short	Enhancing the Anticancer Efficacy of Immunotherapy through Combination with Histone Modification Inhibitors
title_full	Enhancing the Anticancer Efficacy of Immunotherapy through Combination with Histone Modification Inhibitors
title_fullStr	Enhancing the Anticancer Efficacy of Immunotherapy through Combination with Histone Modification Inhibitors
title_full_unstemmed	Enhancing the Anticancer Efficacy of Immunotherapy through Combination with Histone Modification Inhibitors
title_sort	enhancing the anticancer efficacy of immunotherapy through combination with histone modification inhibitors
publisher	MDPI AG
series	Genes
issn	2073-4425
publishDate	2018-12-01
description	In the nucleus of each cell, the DNA is wrapped around histone octamers, forming the so-called “nucleosomal core particles„. The histones undergo various modifications that influence chromatin structure and function, including methylation, acetylation, ubiquitination, phosphorylation, and SUMOylation. These modifications, known as epigenetic modifications (defined as heritable molecular determinants of phenotype that are independent of the DNA sequence), result in alterations of gene expression and changes in cell behavior. Recent work has shown that epigenetic drugs targeting histone deacetylation or methylation modulate the immune response and overcome acquired resistance to immunotherapy. A number of combination therapies involving immunotherapy and epigenetic drugs, which target histone deacetylation or methylation, are currently under various clinical/pre-clinical investigations and have shown promising anticancer efficacy. These combination therapies may provide a new strategy for achieving sustained anticancer efficacy and overcoming resistance.
topic	histone methylation acetylation immunotherapy cancer
url	https://www.mdpi.com/2073-4425/9/12/633
work_keys_str_mv	AT wanyusun enhancingtheanticancerefficacyofimmunotherapythroughcombinationwithhistonemodificationinhibitors AT shutinglv enhancingtheanticancerefficacyofimmunotherapythroughcombinationwithhistonemodificationinhibitors AT hongli enhancingtheanticancerefficacyofimmunotherapythroughcombinationwithhistonemodificationinhibitors AT weicui enhancingtheanticancerefficacyofimmunotherapythroughcombinationwithhistonemodificationinhibitors AT lihuiwang enhancingtheanticancerefficacyofimmunotherapythroughcombinationwithhistonemodificationinhibitors
_version_	1725561114059603968

Enhancing the Anticancer Efficacy of Immunotherapy through Combination with Histone Modification Inhibitors

Similar Items